Coco Kou

Director of Finance/CFO en QHY GROUP .

43 años

Consumer Services

Industrial Services

Health Technology

Perfil

Coco Kou is currently the Chief Financial Officer at QHY Group and the Chief Financial & Accounting Officer at Four Leaf Acquisition Corp.
Prior to these roles, Ms. Kou served as the Chief Financial Officer at Xynomic Pharmaceuticals Holdings, Inc. from 2019 to 2021.
Ms. Kou holds an undergraduate degree and a graduate degree from Peking University, an MBA from the University of Hong Kong, London Business School, and Columbia Business School.

Cargos activos de Coco Kou

Empresas	Cargo	Inicio
QHY GROUP	Director of Finance/CFO	-
FOUR LEAF ACQUISITION CORPORATION	Director of Finance/CFO	01/01/2022

Todos los cargos activos de Coco Kou

Antiguos cargos conocidos de Coco Kou.

Empresas	Cargo	Fin
XYNOMIC PHARMACEUTICALS HOLDINGS, INC.	Director of Finance/CFO	01/01/2021

Ver el detalle de la experiencia de Coco Kou.

Formación de Coco Kou.

Peking University	Graduate Degree
University of Hong Kong	Masters Business Admin
London Business School	Masters Business Admin
Columbia Business School	Masters Business Admin

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Coco Kou.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	2
QHY GROUP	Industrial Services
FOUR LEAF ACQUISITION CORPORATION	Finance

Empresas privadas	1
Xynomic Pharmaceuticals Holdings, Inc. Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China.	Health Technology